- Home
- AGEN vs UNCY Comparison
AGEN vs UNCY Comparison
Compare AGEN & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | UNCY |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 141.8M |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AGEN | UNCY |
|---|---|---|
| Price | $2.98 | $6.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $14.50 | ★ $44.50 |
| AVG Volume (30 Days) | 381.7K | ★ 480.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.25 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $42,877,086.00 | $675,000.00 |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $68.25 | N/A |
| P/E Ratio | $7.88 | ★ N/A |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $1.38 | $0.45 |
| 52 Week High | $7.34 | $7.57 |
Technical Indicators
Market Signals| Indicator | AGEN | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 49.86 |
| Support Level | $2.90 | $5.90 |
| Resistance Level | $3.15 | $6.82 |
| Average True Range (ATR) | 0.18 | 0.36 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 15.79 | 41.59 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.